Literature DB >> 19948393

A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence.

M J Beresford1, D Gillatt, R J Benson, T Ajithkumar.   

Abstract

A substantial proportion of patients who have undergone a radical prostatectomy for localised prostate cancer will have either persistently detectable prostate-specific antigen (PSA) levels or a delayed rise in PSA. The optimum treatment for these situations is not known. The key question is whether the PSA is reflective of local or distant progression. For salvage radiotherapy to be most effective, treatment should be considered before the PSA level is allowed to rise too high, when disease is more likely to be confined to the prostate bed. However, at low PSA levels, current imaging techniques are poor at detecting disease, making it difficult to differentiate local and distant recurrences and to target the radiotherapy appropriately. We review current and investigational imaging techniques, including bone scan, computed tomography, magnetic resonance imaging, positron emission tomography and Prostascint, assessing their utility in the situation of biochemical recurrence after radical prostatectomy. Copyright (c) 2009 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19948393     DOI: 10.1016/j.clon.2009.10.015

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  37 in total

1.  The rising PET: the increasing use of choline PET/CT in prostate cancer.

Authors:  Arturo Chiti; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01       Impact factor: 9.236

Review 2.  Salvage robotic assisted laparoscopic radical prostatectomy: indications and outcomes.

Authors:  Stephen B Williams; Jim C Hu
Journal:  World J Urol       Date:  2010-11-21       Impact factor: 4.226

3.  Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.

Authors:  David M Schuster; Bital Savir-Baruch; Peter T Nieh; Viraj A Master; Raghuveer K Halkar; Peter J Rossi; Melinda M Lewis; Jonathon A Nye; Weiping Yu; F DuBois Bowman; Mark M Goodman
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

Review 4.  PET/MR in prostate cancer: technical aspects and potential diagnostic value.

Authors:  Michael Souvatzoglou; Matthias Eiber; Axel Martinez-Moeller; Sebastian Fürst; Konstantin Holzapfel; Tobias Maurer; Sibylle Ziegler; Stephan Nekolla; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-24       Impact factor: 9.236

5.  The value of multimodality imaging in the investigation of a PSA recurrence after radical prostatectomy in the Irish hospital setting.

Authors:  L C McLoughlin; S Inder; D Moran; C O'Rourke; R P Manecksha; T H Lynch
Journal:  Ir J Med Sci       Date:  2017-06-13       Impact factor: 1.568

6.  Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.

Authors:  Nicola L Robertson; Evis Sala; Matthias Benz; Jonathan Landa; Peter Scardino; Howard I Scher; Hedvig Hricak; Hebert A Vargas
Journal:  J Urol       Date:  2017-02-16       Impact factor: 7.450

Review 7.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

8.  Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer.

Authors:  Susan Evans-Axelsson; Oskar Vilhelmsson Timmermand; Charlotte Welinder; Carl Ak Borrebaeck; Sven-Erik Strand; Thuy A Tran; Bo Jansson; Anders Bjartell
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

9.  Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent.

Authors:  Simon Gauvin; Yannick Cerantola; Eléonore Haberer; Vincent Pelsser; Stephan Probst; Franck Bladou; Maurice Anidjar
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

10.  68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.

Authors:  Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Andrea Farolfi; Cristina Fonti; Filippo Lodi; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-22       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.